Eevia Health Plc's ("Eevia") shares will be listed on Spotlight Stock Market today, June 29, 2021

Eevia Health Plc recently succeeded with an IPO equity round, issuing new 3 451 000 shares with gross proceeds of approx. SEK 26,2 million, leading to a total of 13 951 500 shares in the company as per today's date. Trading in shares will take place from today, June 29, 2021 at Spotlight Stock Market. The short name for the share is EEVIA.

Stein Ulve, CEO: "It is exciting to see Eevia Health listed at Spotlight Stock Market. It is a significant milestone for our Company. Now we may continue focusing on creating growth and value for all constituents of our venture."

See also: Start | Spotlight (

Information about the Eevia Health shares:

Short name:                                 EEVIA 

Share name:                                Eevia Health

ISIN-code:                                    FI4000496658

Orderbook-ID:                              85FD

CFI:                                              ESVUFR

FISN:                                           EEVIA HEALTH/SH

Organization number:                  2825194-4

LEI:                                              743700NO7D0UA8J1MQ31  

Market Segment:                         SPSE

MIC code:                                    XSAT

Tick table/liquidity band #:          1 (Shares and depositary receipts)

Seinäjoki, Finland June 29, 2021 

For more information, please contact: 

Stein Ulve, CEO                                                     Kim Nurmi-Aro, CFO

[email protected]                                  [email protected]

Tel.: +358 400 22 5967                                          +358 504 44 0717

About Eevia

Eevia was founded in 2017 with the mission to address global health problems through the sustainable production and distribution of bioactive plant extracts, which have scientifically documented health benefits. Through utilization of raw material sources, often under-utilized raw materials abundantly available in the Nordic forests, and sometimes inexpensive byproducts from food and woodindustries, Eevia manufactures and markets organically certified nutraceutical ingredients. The products are targeted against immune health, low-grade inflammation, eye and brain health problems and metabolic disorders. The increasing health awareness among consumers, combined with the increased focus on sustainable business models, constitute strong and significant macro-trends. Eevia stands well equipped to capitalize from these trends, resulting in an accelerating growth trajectory.

Eevia is headquartered in Seinäjoki, Finland. As of the end of 2020, the Company had 28 full-time employees and its total revenue for the full year ended December 31st, 2020 was EUR 2.86m. Growth has accelerated in 2021 and extract sales reached EUR 1.9m in the period 1st January - 31st March, corresponding to 560 percent sales growth compared to the same period prior year.

Tuomas Jylhä joins Eevia Health Plc as Interim Chief Financial Officer

Eevia Health Plc ("Eevia" or "The Company") is welcoming Tuomas Jylhä as interim Chief Financial Officer. Gabriella Beni has decided to leave the Company for personal reasons to focus on private matters. Eevia wishes her the very best in her future endeavors. Tuomas Jylhä will take over the position on July 26th.

Eevia Health Plc being followed by Analyst Group

Analyst Group Initiates equity research Coverage of Eevia Health Plc, ("Eevia" or "The Company").

Eevia Health Plc receives a 5,8 MSEK/0,55 MEUR sales order for high concentrate anthocyanin organic bilberry extract

Eevia Health Plc, ("Eevia" or "The Company"), has received a sales order from its Australian distributor Ingredients Plus.

Eevia Health Plc receives a 230 KSEK/21 KEUR starting sales order for a new Lingonberry product to a new customer

Eevia Health Plc, ("Eevia" or "The Company"), has received a 21 KEUR sales order from its Australian distributor Ingredients Plus for a new product made from Lingonberry, after a new customer has decided to launch a new product with the Lingonberry ingredient as a key component.

Eevia Health Plc has secured a credit line of SEK 8 million for working capital purposes to finance continued growth

Eevia Health Plc, ("Eevia" or "The Company"), has entered into an agreement whereby Exelity AB, Sweden will provide a credit line for Eevia of up to SEK 8 million, giving the Company increased working capital flexibility to finance its continued growth.

Communique from the Annual General Meeting in Eevia Health Plc

The Annual General Meeting of Shareholders of Eevia Health Plc, corp. reg. no 2825194-4 (the "Company") was held on June 21, 2022 in Seinäjoki, Finland, whereby the shareholders primarily resolved the following matters:

Eevia Health Plc receives a 2,3 MSEK/0,23 MEUR sales order for organic bilberry extract

Eevia Health Plc, ("Eevia" or "The Company"), has received a sales order from its Australian distributor Ingredients Plus. Ingredients Plus serves leading nutraceutical brands in Oceania and Asia with high-quality ingredients. The end customer is a major natural health company based out of Sydney, Australia selling its products across Asia and Oceania.

Notice of the Annual General Meeting of Shareholders 2022

The shareholders of Eevia Health Abp, company registration number 2825194-4 in Finland, are hereby called for the Annual General Meeting (AGM) to be held on June 21st 2022.

Eevia Health Plc publishes Financial Statements for 2021

Eevia Health Plc's (''Eevia'' or ''the Company'') Financial Statements for 2021 together with the Auditors' report have been published today.

Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Nybrogatan 34
Box 5216
102 45 Stockholm

08-692 21 90

Om beQuoted